A new drug developed by scientists in the US can change the genomic profile of non-healing VLU wounds to a similar profile of a chronic, healing wound.
Chronic wounds are a progression of acute wounds which do not follow the healing stages. It is classified when wounds take longer to heal around 4 weeks and no improvement seen at 8 weeks. Venous leg ulcers fall into the chronic wound category.
A multi-disciplinary research team at the University of Miami conducted a post-market clinical trial to an FDA-approved, bioengineered therapy.
Standard care for non-healing venous leg ulcer is compression therapy. But the team of scientists tested how living-cell therapy can go in the treatment of VLU's.
The research which consisted of random clinical trials used data of those wound treatment with compression therapy. They used data of those patients that only have 40 percent wound reduction after 4 weeks. From that data, they proceeded to a controlled group receiving the living-cell treatment and another group with both treatments.
The team found that the application of living-cell therapy and compression therapy alters the gene expression of the chronic wound profile and shifts to a similar profile with that of an acute wound.
"This is the first time this type of detailed gene expression analysis has been conducted to evaluate the response to a wound healing modality," said Marjana Tomic-Canic, PhD, Director of the Wound Healing and Regenerative Medicine Research Program at the University of Miami.
"This study provides valuable information to researchers and clinicians working to promote healing in chronic wounds," said Gary S. Gillheeney, Sr., President & CEO of Organogenesis, the bio-engineering company which owns the FDA-approved cell therapy treatment for diabetic foot ulcers and venous leg ulcers.
is published in Science Translational Medicine.
See: This Revolutionary Treatment Uses Fish Skin to Treat Burns!